Mosaic Therapeutics has announced the appointment of Dr Stephen Shuttleworth as Chief Scientific Officer. Shuttleworth has been a Venture Partner at Samsara BioCapital, Palo Alto, US since 2019, where his responsibilities included R&D due diligence, new company creation and C-suite level company leadership. He previously served as CSO, COO and… Read More
Oncology therapeutics company Mosaic Therapeutics has appointed Thomas Fuchs as its CEO. Fuchs has over 25 years of experience in leadership positions across early drug development, commercialisation and life cycle management, serving in senior oncology biopharma leadership roles in both oncology-focused biotech and big pharma. He was… Read More
Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical. Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no,… Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More
Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical… Read More
